Slide 1: BioSyent Q1 FY2026 Results
BioSyent BioSyentInc. Inc. Q4 Q1 / FY2026 2023Results Results MARCH 13, 2026 2024 MAY 14, PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Acquisition of Oral Science
Acquisition of Oral Science Acquisition of Privately-Owned Canadian Distributor of Specialized Healthcare Products for Dental Hygiene and Oral Health Share Purchase Agreement (SPA) closed on March 1, 2026 Purchase price of $25.5M (including $6.3M working capital) + $2.0M paid for excess working
Slide 4: 4 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
4 | www.biosyent.com | TSXV: RX 4 | www.biosyent.com | TSXV: RX
Slide 5: Oral Science Overview
Oral Science Overview Growing, revenue-stage oral health company with a successful track record of developing, sourcing, marketing and distributing innovative dental hygiene and oral health products Founded in 2003 Full Year 2025 Annual Financial Results (ASPE) Revenues: $31.2M Based in Brossa
Slide 6: ProForma 2025 Revenue and EBITDA
ProForma 2025 Revenue and EBITDA: BioSyent + Oral Science 80,000 70,000 60,000 50,000 CAD 000'S 40,000 30,000 20,000 10,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Annual Revenue - BioSyent BioSyent 2025 Oral Science 2025 Combined ProForma EBITDA EBITDA (ASP
Slide 7: Oral Science Overview
Oral Science Overview Provisional Purchase Price Allocation (IFRS 3 – Business Combinations)* *Subject to change Provisional Purchase Price Allocation Amount Working capital $8,307,534 Property and equipment 791,813 Intangible assets 17,426,010 Goodwill 3,750,000 Lease liability (475,357) Net assets
Slide 8: Q1 2026 Sales Summary ($)
Q1 2026 Sales Summary ($) (CAD 000’s) Q1 ’26 Q1 ’25 Q1 ‘26 vs. Sales Sales Q1 ’25 (%) Canadian Pharma Sales +9% International Pharma Sales (44%)* *Shipment of Tibelia Intn’l Pharmaceutical 10,803 10,695 +1% order backlog in Q1 2025 Oral Health 2,985 - n/a Insecticides 120 284 (58%) One month of post
Slide 9: Sales, EBITDA and NIAT
Sales, EBITDA and NIAT Quarter ended March 31st (Q1) +27% $3.0M in additional sales during March 2026 from newly- acquired Oral Health segment +35% 10,000 $0.5M in additional EBITDA(1) during March 2026 from Oral Health segment CAD (000's) $0.35M in additional NIAT 5,000 +14% during March 2026 from
Slide 10: Sales, EBITDA and NIAT
Sales, EBITDA and NIAT Quarter ended March 31st (Q1) +27% +35% 10,000 EBITDA +22% adjusted for one- time transaction costs CAD (000's) NIAT +20% adjusted for one- 5,000 +14% time transaction costs + +1% intangibles amortization 10,979 13,908 7,734 2,204 1,769 3,202 2,320 3,639 2,345 0 Q1 2024 Q1 202
Slide 11: Fully Diluted Earnings per Share (TTM)
Fully Diluted Earnings per Share (TTM) TTM and Quarterly Fully Diluted EPS (CAD) 0.80 63 Consecutive Profitable Quarters 0.70 to Q1 2026 0.78 0.60 0.67 0.50 0.59 0.40 0.30 0.20 0.23 0.20 0.20 0.20 0.20 0.14 0.18 0.15 0.17 0.12 0.12 0.13 0.10 0.00 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 20
Slide 12: Fully Diluted Earnings per Share (TTM)
Fully Diluted Earnings per Share (TTM) TTM and Quarterly Fully Diluted EPS (CAD) Q1 2026 0.80 63 Consecutive Adjusted EPS: $0.24 Profitable Quarters 0.70 to Q1 2026 vs. $0.20 Q1 2025 0.78 0.60 0.67 TTM Mar 31, 2026 0.50 0.59 Adjusted EPS: $0.82 vs. $0.61 TTM Mar 31, 2025 0.40 0.30 0.20 0.23 0.20 0.2
Slide 13: Other 2026 Highlights
Other 2026 Highlights Apr 2026: FeraMAX® named #1 recommended iron supplement in Canada for eleventh consecutive year YTD Mar 31, 2026: 100,000 shares repurchased and cancelled under NCIB Mar 13, 2026: Paid quarterly dividend of $0.055/share (+10% increase vs. 2025) May 14, 2026: Declared qu
Slide 14: Most recommended iron supplement in Canada
Most recommended iron supplement in Canada - pharmacists and physicians - 11 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2026 Survey on OTC Counselling and Recomm
Slide 15: Geopolitics, Trade and Economy
Geopolitics, Trade and Economy Uncertainty Armed conflicts Tariffs / Counter-Tariffs Inflationary impacts Transportation Supply Chains Cost of Goods Consumer Behaviour 15 | www.biosyent.com | TSXV: RX
Slide 16: Cash Balance & Return on Equity (RoE)
Cash Balance & Return on Equity (“RoE”) March 31, 2026 35,000 21% 25% • Q1 2026 Cash from Operations; 22% 22% $2.7M 30,000 20% • Q1 2026 NCIB share buybacks: 27,785 $1.4M 25,000 24,899 15% 20,000 • Q1 2026 Net Dividends: $0.6M CAD (000's) RoE % 15,000 10% 14,194 • Q1 2026 Net Debt Proceeds: 10,000 $
Slide 17: Strong Balance Sheet + Cash Generation
Strong Balance Sheet + Cash Generation Supports Ongoing Portfolio Opportunities (CAD 000,000’s) Dec 31, 2025 Mar 1, 2026 Mar 31, 2026 (Acquisition Closing Date) Cash and GICs 31.9 17.2 14.2 Non-cash Working Capital 4.0 8.5 7.8 Non-current Assets 6.4 27.9 27.9 (Short Term Debt)(1) - (8.0) (4.0) (Non-
Slide 18: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue/profit growth & portfolio diversification. Cash-Generating Quarterly Dividends Business Model $7.5 M to Date Q4’22 – Q2’26 Share Buybacks $24.0 M to Date 3.2 million shares repurchased since 2018 •7 new product launche
Slide 19: Stock Information
Stock Information As at May 12, 2026 Exchange & Trading Symbol TSXV: RX 0% May 12, 2026 Closing Stock Price (CAD) (TSXV): $14.65 52 Week Hi/Low (TSXV): $15.80 / $10.65 Issued Common Shares: 11,617,145 Treasury – RSU Shares in Trust (178,827) Outstanding Common Shares: 11,438,318 Options Outstanding
Slide 20: Well Capitalized. Profitable. Growth Assets.
WELL CAPITALIZED. PROFITABLE. GROWTH ASSETS. COMPOUNDING TRACK RECORD. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 20 | www.biosyent.com| |TSXV: www.biosyent.com TSXV:RXRX
Slide 21: Reconciliation of EBITDA to NIAT
Reconciliation of EBITDA to NIAT 1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA